XPERT TECHNOLOGIES Revenue and Competitors

Kuala Lumpur, MY

Location

N/A

Total Funding

Estimated Revenue & Valuation

  • XPERT TECHNOLOGIES's estimated annual revenue is currently $2.1M per year.(i)
  • XPERT TECHNOLOGIES's estimated revenue per employee is $101,500

Employee Data

  • XPERT TECHNOLOGIES has 21 Employees.(i)

XPERT TECHNOLOGIES's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$321.7M160782%$68MN/A
#2
$540.4M260679%$343.2M$10B
#3
$2.6M29-12%N/AN/A
#4
$0.6M8N/AN/AN/A
#5
$4.2M36N/AN/AN/A
#6
$0.4M12-14%$11.7MN/A
#7
$6.7M51N/AN/AN/A
#8
$2.9M29N/AN/AN/A
#9
$2M2067%N/AN/A
#10
$1.6M0N/A$54.8MN/A
#11
$0.3M4N/AN/AN/A
#12
$5.8M50N/AN/AN/A
#13
$0.5M7N/AN/AN/A
#14
$3.3M30-37%$21MN/A
#15
$5.6M48N/AN/AN/A
#16
$4.1M35N/AN/AN/A
#17
$36.8M2362%$2.6MN/A
#18
$2.2M22N/AN/AN/A
#19
$0.3M4N/AN/AN/A
#20
$0.3M4N/AN/AN/A
Add Company

What Is XPERT TECHNOLOGIES?

keywords:N/A

N/A

Total Funding

21

Number of Employees

$2.1M

Revenue (est)

N/A

Employee Growth %

N/A

Valuation

N/A

Accelerator

XPERT TECHNOLOGIES News

2022-04-17 - Molecular tests for TB: A Cochrane review

This was 12 years ago, with the launch of Xpert MTB/RIF, ... Implementation of new diagnostic technologies, like those considered in this...

2022-04-17 - Molecular tests for TB: Global rollout of rapid molecular tests ...

This was 12 years ago, with the launch of Xpert MTB/RIF, ... Implementation of new diagnostic technologies, like those considered in this...

2022-04-17 - Molecular tests for TB: A Cochrane review

This was 12 years ago, with the launch of Xpert MTB/RIF, ... Implementation of new diagnostic technologies, like those considered in this...

2022-04-17 - Molecular tests for TB: Global rollout of rapid molecular tests ...

This was 12 years ago, with the launch of Xpert MTB/RIF, ... Implementation of new diagnostic technologies, like those considered in this...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$2.1M21-9%N/A
#2
$3M21-30%N/A
#3
$4.9M22-19%N/A
#4
$3.5M2222%N/A
#5
$4.9M2247%N/A